Schedule 13G/A: Eli Lilly Discloses 0 Ownership in Immunocore

Rhea-AI Filing Summary

This Schedule 13G/A reports that Eli Lilly & Co. and Eli Lilly S.A. filed an amendment concerning their holdings in Immunocore Holdings plc ordinary shares (CUSIP 54258D105) related to the reporting event dated 09/30/2025. Both reporting entities state they beneficially own 0 ordinary shares, representing 0.0% of the class, with 0 shares of sole or shared voting or dispositive power. The filing lists issuer headquarters at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, UK. Signatures show the amendment was executed by Christopher Anderson as Attorney-in-Fact for both filers on 10/03/2025, and reference previously filed powers of attorney incorporated by reference.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Immunocore Holdings plc

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

54258D105

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 54258D105

1

Names of Reporting Persons

ELI LILLY & Co

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

INDIANA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 54258D105

1

Names of Reporting Persons

ELI LILLY S.A.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Immunocore Holdings plc
(b)	Address of issuer's principal executive offices: 90 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM, OX14 4RY.
Item 2.
(a)	Name of person filing: Eli Lilly S.A. Eli Lilly and Company
(b)	Address or principal business office or, if none, residence: c/o Lilly Corporate Center Indianapolis, Indiana 46285
(c)	Citizenship: Eli Lilly S.A. Switzerland societe anonyme Eli Lilly and Company Indiana corporation
(d)	Title of class of securities: Ordinary Shares
(e)	CUSIP No.: 54258D105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of Cover Sheet.
(b)	Percent of class: See Item 11 of Cover Sheet.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of Cover Sheet.
	(ii) Shared power to vote or to direct the vote: See Item 6 of Cover Sheet.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of Cover Sheet.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of Cover Sheet.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ELI LILLY & Co

Signature:	/s/ Christopher Anderson
Name/Title:	Attorney-in-Fact
Date:	10/03/2025

ELI LILLY S.A.

Signature:	/s/ Christopher Anderson
Name/Title:	Attorney-in-Fact
Date:	10/03/2025

Comments accompanying signature: This Schedule 13G/A was executed pursuant to a power of attorney for Eli Lilly and Company previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as Exhibit 99.3 to a filing on Schedule 13G for the Issuer on February 10, 2022. This Schedule 13G/A was executed pursuant to a power of attorney for Eli Lilly S.A. previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as Exhibit 99.2 to a filing on Schedule 13G for the Issuer on February 10, 2022.

FAQ

Does Eli Lilly (IMCR) hold shares of Immunocore as of this filing?

No. The filing states Eli Lilly & Co. and Eli Lilly S.A. each beneficially own 0 shares, representing 0.0% of Immunocore ordinary shares.

What class of securities is covered in this Schedule 13G/A for IMCR?

The filing covers Ordinary Shares of Immunocore Holdings plc (CUSIP 54258D105).

When is the event date that triggered this Schedule 13G/A?

The date of the event requiring this filing is 09/30/2025.

Who signed the amendment to the Schedule 13G/A?

The amendment was signed by Christopher Anderson as Attorney-in-Fact for both Eli Lilly & Co. and Eli Lilly S.A. on 10/03/2025.

Where are Immunocore's principal executive offices listed in the filing?

The filing lists the issuer's principal executive offices at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY.